Use of medicine combination comprising carvedilol and angiotensin II recipient antagon in preparing medicine for treating kidney disease

An angiotensin and receptor antagonist technology, applied in the field of medicine, can solve the problems that have not yet been discovered, and achieve the effect of wide application range and good synergistic therapeutic effect

Active Publication Date: 2009-04-29
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The protective effect of angiotensin II receptor antagonists on the kidneys is well known. Through searching, there have been reports on the combined use of carvedilol and valsartan in the treatment of refractory heart failure. Dirol and angiotensin II receptor antagonist drugs are used to treat nephropathy. The present invention has special curative effect on nephropathy and carvedilol is effective in treating hypertension by using publicly known angiotensin II receptor antagonist drugs. Significant effects in treatment, through experiments found that the combined application of the two does have a synergistic effect on the treatment of kidney disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of medicine combination comprising carvedilol and angiotensin II recipient antagon in preparing medicine for treating kidney disease
  • Use of medicine combination comprising carvedilol and angiotensin II recipient antagon in preparing medicine for treating kidney disease
  • Use of medicine combination comprising carvedilol and angiotensin II recipient antagon in preparing medicine for treating kidney disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] compound tablet

[0017] Carvedilol 10g

[0018] Valsartan 30g

[0019] Microcrystalline cellulose 10g

[0020] Starch 140g

[0021] Magnesium stearate 2g

[0022] Sodium carboxymethyl starch 20g

[0023] 10% starch slurry Appropriate amount

[0024] Preparation process: Pass the prescribed amount of carvedilol and valsartan through a 100-mesh sieve, sodium carboxymethyl starch, starch, and microcrystalline cellulose through a 80-mesh sieve, mix well, add an appropriate amount of 10% starch slurry to granulate, and dry Finally, magnesium stearate is added and compressed into tablets to obtain the product.

Embodiment 2

[0026] Compound powder

[0027] Carvedilol 2.5g

[0028] Irbesartan 62.5g

[0029] Microcrystalline Cellulose 10g

[0030] Starch 10g

[0031] Preparation process: Pass the prescribed amount of carvedilol and irbesartan through a 100-mesh sieve, starch and microcrystalline cellulose through a 80-mesh sieve, mix evenly, and pack separately to obtain the product.

Embodiment 3

[0033] compound tablet

[0034] Carvedilol 10g

[0035] Candesartan cilexetil 10g

[0036] Microcrystalline cellulose 35g

[0037] Starch 140g

[0038] 10% starch slurry Appropriate amount

[0039] Sodium carboxymethyl starch 20g

[0040] Magnesium stearate 2g

[0041] Preparation process: Pass the prescribed amount of carvedilol and candesartan cilexetil through a 100-mesh sieve, sodium carboxymethyl starch, starch, and microcrystalline cellulose through a 80-mesh sieve, mix well and add an appropriate amount of 10% starch slurry to granulate , after drying, add magnesium stearate and press into tablets to obtain.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides the usages of a drug composition comprising the active components of carvedilol and an angiotensin II receptor antagonist for preparing a drug which can cure nephropathy. The cooperation effect of the carvedilol and the angiotensin II receptor antagonist are used for developing a method which is more effective in curing the nephropathy. The drug composition has remarkable effects when being used for curing nephropathy, diabetic nephropathy, hypertensive nephropathy, and the like.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the use of a pharmaceutical composition containing carvedilol and an angiotensin II receptor antagonist in the preparation of medicines for treating nephropathy. Background technique [0002] With the continuous development of medical science, people gradually have a deeper understanding of the harm of kidney disease. According to the evidence of epidemiological investigation, chronic kidney disease has become a major disease that threatens public health all over the world. This is a public health expert and It is an objective fact that medical experts have only realized in the past ten years. Chronic kidney disease includes a variety of kidney diseases: such as chronic glomerulonephritis, interstitial nephritis, chronic urinary tract infection, renal tubular disease, diabetic nephropathy, lupus nephritis, renal vascular disease and renal insufficiency uremia. If th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/41A61K31/4178A61K31/4184A61K31/519A61K9/08A61K9/10A61K9/14A61K9/16A61K9/20A61K9/48A61P3/10A61P9/12A61P13/12A61K31/404
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap